Li Liying, Duan Linjia, Wang Bingxue, Wang Kexin, Niu Guodong, He Sen, Tang Jiong
Department of Cardiology, Fuwai Yunnan Cardiovascular Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, China.
Department of Cardiology, West China Hospital of Sichuan University, Chengdu, China.
Sci Rep. 2025 Apr 11;15(1):12422. doi: 10.1038/s41598-025-95904-z.
Previous studies found that frailty has a significant impact on the prognosis of hypertensive patients. However, most of the previous studies only focused on baseline frailty status. The association of changes in frailty with mortality in hypertensive patients is little known. Therefore, we aimed to investigate the association of frailty transitions with all-cause mortality and cardiovascular death in older adults with hypertension. A total of 1827 older hypertensive participants age ≥ 65 years from the Chinese Longitudinal Healthy Longevity Study were included. Frailty status was assessed by a 35-item frailty index (FI). Changes in frailty were evaluated by frailty at baseline (wave 2011) and the second survey (wave 2014), and four types of changes in frailty were identified: remaining non-frail, frail to non-frail, non-frail to frail, and remaining frail. The accelerated failure time model was used to evaluate the association of changes in frailty status with all-cause mortality and cardiovascular death. The dose-response relationship between annual changes in FI and mortality was analyzed using restricted cubic splines (RCS). During 6128.9 person-years of follow-up, a total of 623 all-cause mortality and 131 cardiovascular deaths were recorded. Compared to the remaining non-frail group, the fully adjusted time ratios (TRs) of all-cause mortality were 0.75 (95% CI 0.59-0.96, p = 0.025), 0.48 (95% CI 0.41-0.57, p < 0.001), and 0.45 (95% CI 0.37-0.55, p < 0.001) in the frail to non-frail group, non-frail to frail group, and remaining frail group, respectively. After adjusting for potential confounding variables, the adjusted TRs of cardiovascular death were 0.63 (95% CI 0.36-1.11, p = 0.108), 0.34 (95% CI 0.23-0.48, p < 0.001), and 0.34 (95% CI 0.22-0.53, p < 0.001) in the frail to non-frail group, non-frail to frail group, and remaining frail group, respectively. RCS analysis revealed a non-linear relationship between annual changes in FI and all-cause mortality and cardiovascular death (both p for non-linearity < 0.05). Stratified and sensitivity analysis showed similar results. Frailty is a dynamic process, and worsening in frailty status accelerated all-cause mortality and cardiovascular death in older adults with hypertension. In contrast, improvement in frailty status prolonged the survival time of patients.
既往研究发现,衰弱对高血压患者的预后有显著影响。然而,既往大多数研究仅关注基线衰弱状态。衰弱变化与高血压患者死亡率之间的关联鲜为人知。因此,我们旨在研究衰弱转变与老年高血压患者全因死亡率和心血管死亡之间的关联。纳入了中国健康与养老追踪调查中1827名年龄≥65岁的老年高血压参与者。通过35项衰弱指数(FI)评估衰弱状态。根据基线(2011年)和第二次调查(2014年)时的衰弱情况评估衰弱变化,确定了四种衰弱变化类型:一直非衰弱、从衰弱转变为非衰弱、从非衰弱转变为衰弱、一直衰弱。采用加速失效时间模型评估衰弱状态变化与全因死亡率和心血管死亡之间的关联。使用受限立方样条(RCS)分析FI年度变化与死亡率之间的剂量反应关系。在6128.9人年的随访期间,共记录了623例全因死亡和131例心血管死亡。与一直非衰弱组相比,从衰弱转变为非衰弱组、从非衰弱转变为衰弱组和一直衰弱组全因死亡率的完全调整时间比(TRs)分别为0.75(95%CI 0.59 - 0.96,p = 0.025)、0.48(95%CI 0.41 - 0.57,p < 0.001)和0.45(95%CI 0.37 - 0.55,p < 0.001)。在调整潜在混杂变量后,从衰弱转变为非衰弱组、从非衰弱转变为衰弱组和一直衰弱组心血管死亡的调整TRs分别为0.63(95%CI 0.36 - 1.11,p = 0.108)、0.34(95%CI 0.23 - 0.48,p < 0.001)和0.34(95%CI 0.22 - 0.53,p < 0.001)。RCS分析显示FI年度变化与全因死亡率和心血管死亡之间存在非线性关系(非线性检验p值均<0.05)。分层分析和敏感性分析结果相似。衰弱是一个动态过程,衰弱状态恶化会加速老年高血压患者的全因死亡率和心血管死亡。相反,衰弱状态改善会延长患者的生存时间。